Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupPlasma cell neoplasmsDiseaseAmyloidosisSubgroupAL AmyloidosisICD10E85.-MeSHAmyloidosisSequenceANDROMEDA: DEXA(20/20)/CYCL300/DRTM1800/BORT1,3, AL amyloidosis, C1-2 (PID1631) -|- C3-6 (PID1632) -|-C7+ (PID1633)DEXA40/MELP0.22/BORT1.3, AL-Amyloidosis, C1-2 (PID1638) -|- C3-8 (PID1639)DRTM(8/8/16), AL amyloidosis, C1 (PID1473) -|- C2 (PID1478) -|- C3-6 (PID1479) -|- C7+ (PID1480)DRTM(8/8/16)/LENA5/DEXA20, AL amyloidosis, C1 (PID2444) -|- C2 (PID2445) -|- C3-6 (PID2446) -|- C7+ (PID2447)DRTM1800/BORT1.0/DEXA20, AL-Amyloidosis, C1-2 (PID2456) -|- C3-6 (PID2457) -|- C7+ (PID2458).DRTM1800/LENA5/DEXA20, AL-Amyloidosis, C1-2 (PID2452) -|- C3-6 (PID2453) -|- C7+ (PID2454)ChemotherapyChemo-substanceBendamustineBortezomibCyclophosphamideDaratumumabDexamethasoneIxazomibLenalidomideMelphalanChemo-substanceBendamustineBortezomibCyclophosphamideDaratumumabDexamethasoneIxazomibLenalidomideMelphalanChemo-substanceBendamustineBortezomibCyclophosphamideDaratumumabDexamethasoneIxazomibLenalidomideMelphalanChemo-substanceBendamustineBortezomibCyclophosphamideDaratumumabDexamethasoneIxazomibLenalidomideMelphalanNo. Substances1234 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronItraconazoleMontelukastPantoprazoleParacetamolPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronItraconazoleMontelukastPantoprazoleParacetamolPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronItraconazoleMontelukastPantoprazoleParacetamolPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronItraconazoleMontelukastPantoprazoleParacetamolPrednisoloneNo. Substances1234568910Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlAstheniaAtrial FibrillationBleedingCardiotoxicityColitisConstipationDiarrheaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Heart FailureHepatotoxicityHypertensionHypokalemiaHyponatremiaHypotensionInfectionsInfusion ReactionLeukopeniaLymphopeniaNeuropathyNeurotoxicityNeutropeniaPneumoniaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorCohen OC Dietrich SDispenzieri A Hegenbart UKastritis EKimmich CRLentzsch SPalladini GReece DSanchorawala VVenner CPDiseaseAL-AmyloidoseAL-Amyloidose, mindestens 1 Vortherapie, ECOG 0-2AL-Amyloidose, neu diagnostiziertAL-Amyloidose, neu diagnostiziert, ECOG 0-2AL-Amyloidose, neu diagnostiziert, nicht geeignet für ASCTAL-Amyloidose, neu diagnostiziert oder rezidiviertAL-Amyloidose, nicht für ASCT geeignet, mindestens 1 Vortherapie, ECOG 0-2AL-Amyloidose, nicht vorbehandelt, nicht geeignet für ASCTAL-Amyloidose, rezidiviert oder therapierefraktär, 1-2 VortherapienAL-Amyloidose, therapierefraktär oder rezidiviertAL-Amyloidose, vorbehandeltAL-Amyloidose, vorbehandelt, ECOG 0-1, Kreatinin-Clearance über 40 ml/min, EF über 40%AL-Amyloidose ohne fortgeschrittene kardiale Beteiligung (Stadium IIIb nach Mayo 2004/European cardiac staging system), nicht geeignet für eine ASCTNeu diagnostizierte AL-Amyloidose, nicht geeignet für ASCTOriginAmyloidosis Research and Treatment Center, Pavia, Italy, ANDROMEDA trialBoston University School of Medicine, United StatesColumbia University Medical Center, New York, USADivision of Hematology, Mayo Clinic, Rochester, NY, USA, TOURMALINE-AL1Heidelberg University Hospital, Heidelberg, GermanyNational Amyloidosis Centre, University College London (Royal Free Campus), London, UKNational and Kapodistrian University of Athens, School of Medicine, Athens, GreecePrincess Margaret Hospital, Toronto, CanadaUniversity College London Medical School, London, United KingdomUniversity Hospital Pavia and University of Pavia, ItalyUniversity of Athens School of Medicine, Athens, GreeceUniversity of Heidelberg, Heidelberg, GermanyProtocols in Revision 29 protocols foundBortezomib 1,3, AL Amyloidosis (PID1510 V1.0)Bortezomib 1.6, AL Amyloidosis (PID1509 V1.0)Daratumumab (8/8/16) / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 1 (PID2444 V1.0)Daratumumab (8/8/16), AL amyloidosis, cycle 1 (PID1473 V1.0)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 2 (PID2445 V1.0)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 3-6 (PID2446 V1.0)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 7+ (PID2447 V1.0)Daratumumab 16, AL amyloidosis, cycle 2 (PID1478 V1.0)Daratumumab 16, AL Amyloidosis, cycle 3-6 (PID1479 V1.0)Daratumumab 16, AL amyloidosis, cycle 7+ (PID1480 V1.0)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20 - Daratumumab 1800 maintenance, AL-Amyloidosis, cycle 7+. (PID2458 V1.0)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20, AL-Amyloidosis, cycle 1-2. (PID2456 V1.0)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20, AL-Amyloidosis, cycle 3-6. (PID2457 V1.0)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 1-2 (PID2452 V1.0)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 3-6 (PID2453 V1.0)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 7+ (PID2454 V1.0)Daratumumab 1800, maintenance after Dexamethasone (20/20/40) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3 - Daratumumab 1800 maintenance, AL amyloidosis, cycle 7+ (PID1633 V1.0)Dexamethasone (20/20) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3, AL amyloidosis, cycle 1-2 (PID1631 V1.1)Dexamethasone (20/20/40) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3, AL Amyloidosis, cycle 3-6 (PID1632 V1.1)Dexamethasone 20 / Bendamustine 100, AL-Amyloidosis (PID1513 V2.0)Dexamethasone 20 / Bortezomib 1.3, AL Amyloidosis (PID1511 V1.0)Dexamethasone 20 / Cyclophosphamide 350 / Bortezomib 1.0, AL amyloidosis (PID1514 V1.0)Dexamethasone 20 / Melphalan 0.15 / Lenalidomide 10, AL Amyloidosis (PID1512 V1.1)Dexamethasone 20 / Melphalan 0.22, AL-Amyloidosis (PID1506 V2.0)Dexamethasone 20 / Melphalan 16, AL Amyloidosis (PID1508 V2.0)Dexamethasone 40 / Melphalan 0.22 / Bortezomib 1.3, AL amyloidosis, cycle 1-2 (PID1638 V1.0)Dexamethasone 40 / Melphalan 0.22 / Bortezomib 1.3, AL amyloidosis, cycle 3-8 (PID1639 V1.0)Ixazomib 4 / Dexamethasone 20, AL-Amyloidosis (PID2534 V1.0)Ixazomib 4 / Lenalidomide 15 / Dexamethasone 40, AL-Amyloidosis (PID2477 V1.0)
